XERS
HEALTHCAREXeris Biopharma Holdings Inc
$6.37+0.14 (+2.25%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving XERS Today?
No stock-specific AI insight has been generated for XERS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.30$10.08
$6.37
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-6.2%
Profit Margin0.0%
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding172.6M
XERS News
20 articles- Xeris Biopharma Q1 Earnings Call HighlightsMarketbeat·May 9, 2026
- Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's ChangedYahoo Finance·May 8, 2026
- Xeris (XERS) Q1 2026 Earnings Call TranscriptMotley Fool·May 7, 2026
- Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 7, 2026
- Xeris Biopharma Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 23, 2026
- Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)?Yahoo Finance·Apr 13, 2026
- Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·Apr 3, 2026
- Xeris Biopharma Balances New Profitability With Recorlev Patent BattlesYahoo Finance·Mar 3, 2026
- Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...Yahoo Finance·Mar 2, 2026
- Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 2, 2026
- Xeris Biopharma (XERS) Q4 2025 Earnings TranscriptMotley Fool·Mar 2, 2026
- Xeris Biopharma Q4 Earnings Call HighlightsMarketbeat·Mar 2, 2026
- Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to SayYahoo Finance·Mar 2, 2026
- Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass EstimatesYahoo Finance·Mar 2, 2026
- Xeris Biopharma: Q4 Earnings SnapshotYahoo Finance·Mar 2, 2026
- Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 GuidanceYahoo Finance·Mar 2, 2026
- A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev ExclusivityYahoo Finance·Mar 1, 2026
- Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement LawsuitYahoo Finance·Feb 26, 2026
All 20 articles loaded
Price Data
Open$6.17
Previous Close$6.23
Day High$6.33
Day Low$6.10
52 Week High$10.08
52 Week Low$4.30
52-Week Range
$4.30$10.08
$6.37
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-6.2%
Profit Margin0.0%
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding172.6M
About Xeris Biopharma Holdings Inc
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—